Scarica l'app Stockscreener
328.93
0.86%
2.79
Dopo l'orario di chiusura:
328.93
Natera Inc Borsa (NTRA) Ultime notizie
Understanding Momentum Shifts in (NTRA) - Stock Traders Daily
Did Earnings Beat Just Shift Natera (NTRA) Investment Narrative? - webull.com
Natera(NTRA.US) Officer Sells US$16.4 Million in Common Stock - Moomoo
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares By Investing.com - Investing.com South Africa
Natera executive chairman Matthew Rabinowitz sells $16.4m in shares - Investing.com
Executive chair of Natera (NTRA) sells 50,000 shares - Stock Titan
Insider at Natera (NTRA) plans stock sale, with size detailed in new SEC notice - Stock Titan
NTRA Maintains Buy Rating by UBS -- Price Target Raised to $435 - GuruFocus
3 Reasons Investors Love Natera (NTRA) - Yahoo Finance
UBS Adjusts Price Target on Natera to $435 From $290, Keeps Buy Rating - Moomoo
Jim Cramer Calls Natera (NTRA) “a Promising Story” - Yahoo Finance
Net current asset value per share of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - tradingview.com
Fed. Circ. Urged To Overturn Natera's Cancer Test Patent Win - Law360
Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) - The Motley Fool
NTRA Initiated Coverage by Rothschild & Co -- Price Target Set a - GuruFocus
Can Natera (NTRA) Justify Its Valuation As Signatera Lymphoma Data Lifts Sentiment? - simplywall.st
Rothschild Redburn initiates Natera stock with buy on MRD leadership By Investing.com - Investing.com Nigeria
Rothschild Redburn initiates Natera stock with buy on MRD leadership - Investing.com
Debt to assets ratio of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Net debt of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - tradingview.com
Natera, Inc. (NTRA) Stock Analysis: A $47.31 Billion Healthcare Innovator with Strong Buy Ratings - DirectorsTalk Interviews
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAD - TradingView
Price to earnings forward of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - tradingview.com
Diluted earnings per share (diluted EPS) of NATERA INC CEDEAR EACH 51 REPR 1 COM (USD) – BCBA:NTRA.CI - TradingView
Gross profit of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRA - TradingView
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA.CI - tradingview.com
Natera Inc Cert Deposito Arg Repr 0.019607 Sh Revenue Breakdown – BCBA:NTRA - tradingview.com
Guggenheim maintains Buy on Natera, raises target to $290 - scanx.trade
Net income before discontinued operations of Natera Inc Cert Deposito Arg Repr 0.019607 Sh – BCBA:NTRAC - TradingView
The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership - simplywall.st
Natera CEO Steven Chapman sells $545k in NTRA shares By Investing.com - Investing.com South Africa
Natera president Solomon Moshkevich sells over $5.9m in shares By Investing.com - Investing.com South Africa
Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years - benzinga.com
Natera stock trades near 52-week high as guidance and regulatory wins support growth - ad-hoc-news.de
Natera Inc (NTRA) CEO and President Steven Chapman Sells 1,698 S - GuruFocus
Natera president Solomon Moshkevich sells over $5.9m in shares - Investing.com
Natera CEO Steven Chapman sells $545k in NTRA shares - Investing.com
Natera (NASDAQ: NTRA) exec sells shares for taxes and under pre-set plan - Stock Titan
Natera Unlocks Broader Signatera Adoption With FDA, PMDA And NCCN Milestones! - Smartkarma
Natera: $8.25M Prenatal Test Class Action Settlement Approved - Wansom AI
I would put Natera on my watch list and not chase the stock here, says Jim Cramer - CNBC
After recent stock sales, Natera (NASDAQ: NTRA) exec files notice to sell more shares - Stock Titan
Planned stock sale by Natera (NTRA) holder follows 41,124-share trade - Stock Titan
Natera (NASDAQ: NTRA) executive plans nearly $1M share sale after $2M in recent trades - Stock Titan
NTRA Looks 47.2% Overvalued on GF Value™ - GuruFocus
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma - Stock Titan
Natera teams with Angiex on cancer drug trial monitoring - Fierce Biotech
Pretax income of Natera, Inc. – LSX:A14VPJ - TradingView
Natera, Inc. (NTRA) Stock Analysis: A Healthcare Powerhouse with a 3.21% Upside Potential - DirectorsTalk Interviews
Natera Stock (NTRA) Opinions on Recent Price Surge - moomoo.com
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? - The Motley Fool
Natera president John Fesko sells $2.1m in company stock By Investing.com - Investing.com Nigeria
Natera (NASDAQ: NTRA) exec gets 20K RSUs, sells shares for taxes - Stock Titan
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera - Eastern Progress
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer - finance.yahoo.com
Natera president John Fesko sells $2.1m in company stock - Investing.com
Natera (NTRA) Q1 2025 Earnings: Results, Market Reaction & History - 247wallst.com
How Investors May Respond To Natera (NTRA) New MRD Trial Deal And Duquesne Stake Expansion - Yahoo Finance
Is Natera’s (NTRA) Kupando MRD Deal a Stepping Stone in Its Oncology Strategy? - simplywall.st
1.74%
0.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):